Skip to content

Repetitive transcranial magnetic stimulation for Alzheimer's disease: randomized double-blind controlled trials

Effectiveness of high-frequency versus low-frequency repetitive transcranial magnetic stimulation in patients with Alzheimer's disease (AD): randomized double-blind controlled trials

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041625
Enrollment
Unknown
Registered
2021-01-01
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

HF-rTMS:HF-rTMS
LF-rTMS:LF-rTMS

Sponsors

The First Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The age ranged from 50 to 85 years old; 2. The patients with Alzheimer's disease who were diagnosed after screening in a regular Grade-A hospital system had not received transcranial magnetic stimulation, transcortical electrical stimulation, deep brain electrical stimulation, vagus nerve electrical stimulation and other treatments in the past; Or 3. memory and cognitive function decreased in recent one year, MMSE OR MoCa score was 11-26 (more than 6 years of Education) or 11-22 (less than 6 years of Education); MRI showed medial temporal atrophy (hippocampus, entorhinal cortex, amygdala), MTA visual evaluation scale >= 2; or PET-CT showed decreased FDG absorption in medial temporal lobe.

Exclusion criteria

Exclusion criteria: 1. There is a history of severe brain organic lesions or brain surgery, such as brain space occupying, hydrocephalus, intracranial hematoma, etc.; 2. There are serious complications, such as frequent seizures, brain tumor surgery, intracranial infection, serious heart disease, lung disease, mania, severe mental disorders, etc.; 3. The implanted pacemaker, defibrillator, cochlear implant or other nerve stimulator, or the implanted steel plate and other materials cannot cooperate with the completion of transcranial magnetic stimulation therapy and magnetic resonance imaging; 4. Frontotemporal dementia, vascular dementia, Lewy body dementia and other diseases; 5. White matter lesions with Fazekas score > 3 or cerebral infarction in medial temporal lobe were excluded 6. In severe hydrocephalus, Evans index was greater than 0.33, frontal horn became sharp < 100; 7. Ohters referred to the NINCDS-ADRDA exclusion criteria (revised - 2007).

Design outcomes

Primary

MeasureTime frame
Mini-mental state examination (MMSE);

Secondary

MeasureTime frame
AD Assessment Scale-cognitive subscale (ADAS-cog);Generalized anxiety disorder scale;activities of daily living scale (ADL);Center for Epidemiological Studies Depression Scale;Montreal Cognitive Assessment (MOCA);

Countries

China

Contacts

Public ContactJian Chen

The First Affiliated Hospital of Shantou University Medical College

drchen@stu.edu.cn+86 13360802157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026